Anthony Olszanski, MD

Anthony Olszanski, MD, RPh

Oncology Philadelphia, PA

Phase 1 early drug development for oncologic indications. Practice focus on GI malignancies/melanoma.


Office Address

  • 333 Cottman Ave
    Medical Staff Office
    Philadelphia, PA 19111
    Phone: (215) 728-6900
    Fax: (215) 214-3229

Anthony Olszanski, MD, RPh

Oncology Philadelphia, PA

Phase 1 early drug development for oncologic indications. Practice focus on GI malignancies/melanoma.

Clinical Specialties & Interests

  • Oncology: General Oncology, Gastrointestinal Cancer, Melanoma
  • Clinical Interests: Gastrointestinal Neoplasms; Clinical Trials as Topic; Pancreatic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Phase 1 Early Drug Development

Education & Training

  • Dartmouth-Hitchcock Medical CenterDartmouth-Hitchcock Medical Center
  • Dartmouth-Hitchcock Medical CenterDartmouth-Hitchcock Medical Center
  • Dartmouth-Hitchcock Medical CenterDartmouth-Hitchcock Medical Center
  • Rutgers New Jersey Medical SchoolRutgers New Jersey Medical School
  • University of Montana

Certifications & Licensure

  • PA State Medical LicensePA State Medical License2009 - 2016
  • American Board of Internal MedicineMedical Oncology
  • American Board of Clinical PharmacologyClinical Pharmacology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 CertificationEpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Accelerating Anticancer Agent Development and ValidationAmerican Association for Cancer Research, 2006
  • Methods in Clinical Cancer ResearchAmerican Association for Cancer Research, 2003

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase I dose-escalation study of LCL161, an oral IAP inhibitor, in patients with advanced solid tumors.  Infante JR, Dees EC, Olszanski AJ, JCO
  • Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial.  Slingluff CL, Petroni GR, Molhoek KR, Olszanski AJ, CCR
  • Phase I study of axitinib combined with paclitaxel, docetaxel, or capecitabine in patients with advanced solid tumors.  Martin LP, Kozloff MF, Herbst RS et al. and Olszanski AJ, British Journal of Cancer, 107; 1268-1276

Abstracts/Posters

  • Dose-escalation Phase 1 study of cabazitaxel (Cbz) + gemcitabine (Gem) in patients (pts) with metastatic or unresectable advanced solid malignancy. Rixe O, Puzanov I., LoRusso P, et al and Olszanski AJ, ESMO (2012) Abstract 497P
  • Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies. Slingluff CL, et al and Olszanski AJ, ASCO (2012) Abstract 8530
  • Phase 1 and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors. Faivre S, Olszanski AJ, ASCO (2012) Abstract 2554

Grant Support

  • Cancer Genome Institute Clinical Research Pilot GrantFox Chase Cancer Center
    2013 - Present

Committees

  • Research Reivew Committee, FCCC Member 2009 - Present
  • Pharmacy & Therapeutics Committee, FCCC Chair 2012 - Present
  • American Board of Clinical Pharmacology, Credentials Committee Chair 2011 - Present
  • FCCC Cancer Genome Institute Senior Medical Advisor 2012 - Present
  • FCCC Genomic Advisory Board Chair 2012 - Present
  • National Comprehensive Cancer Network, Melanoma Panel Member 2010 - Present
  • Data Safety Monitoring Board, FCCC Member 2012 - Present
  • NCCN Investigator Steering Committee Member 2012 - Present

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • AmeriHealth Direct POS
  • Amerihealth HMO
  • AmeriHealth PPO
  • BCBS Blue Card PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Great West PPO
  • Humana ChoiceCare Network PPO
  • IBC Keystone HMO / POS
  • IBC Personal Choice PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • QualCare HMO
  • QualCare PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
  • The full profile is locked and available to verified physicians only.
    Join over 50% of U.S. physicians already on Doximity and get access to this and over 700,000 physician CVs. Find your physician profile

Physicians, view Dr. Olszanski's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV